MPG.eBooks - Search Results - "Multiple Sclerosis"

1

Vitamin D for the treatment or prevention of multiple sclerosis : a review of the clinical effectiveness

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis / prevention & control...”

Read Now

2

Management of relapsing-remitting multiple sclerosis

Published 2013

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Read Now

3

Management of relapsing-remitting multiple sclerosis

Published 2013

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Read Now

4

Pharmacoeconomic review report: Cladribine (Mavenclad) (EMD Serono) : indication : as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (R...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Read Now

5

Daclizumab (Zinbryta)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Read Now

6

Pharmacoeconomic review report: Cladribine (Mavenclad) (EMD Serono) : indication : as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (R...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Read Now

7

Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)

Published 2017

CADTH

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Read Now

8

Patient group input submissions: Ocrelizumab (Ocrevus) (Hoffmann-La Roche Limited)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Chronic Progressive / drug therapy...”

Read Now

9

Clinical review report: Cladribine (Mavenclad) (EMD serono)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Read Now

10

Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)

Published 2018

CADTH

Subjects: “...Multiple Sclerosis, Chronic Progressive / drug therapy...”

Read Now

11

Pharmacoeconomic review report: Daclizumab (Zinbryta)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Read Now

12

Pharmacoeconomic review report: Daclizumab (Zinbryta)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Read Now

13

Pharmacoeconomic review report: Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)

Published 2017

CADTH

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Read Now

14

Comparative clinical and cost-effectiveness of drug therapies for relapsing-remitting multiple sclerosis : project protocol

Published 2012

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Read Now

15

CADTH Canadian Drug Expert Committee recommendation: Cladribine (Mavenclad -- EMD Serono) : indication: relapsing-remitting multiple sclerosis

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Read Now

16

Teriflunomide (Aubagio) (14 mg film-coated tablet)

Published 2014

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Read Now

17

Patient group input submissions: AbobotulinumtoxinA (Dysport therapeutic ULS) for the symptomatic treatment of focal spasticity affection the upper limbs in adults

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis / drug therapy...”

Read Now

18

CADTH Canadian Drug Expert Committee recommendation: Daclizumab (Zinbryta -- Biogen Canada Inc.) : indication: relapsing-remitting multiple sclerosis

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Read Now

19

Pharmacoeconomic review report: Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Chronic Progressive / drug therapy...”

Read Now

20

Recommendations for drug therapies for relapsing-emitting multiple sclerosis

Published 2013

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Narrow Search